Overview

A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) nave Participants Participants With Early Rheumatoid Arthritis

Status:
RECRUITING

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

The study is a randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP1189 administered at the doses of 40, 70, or 100 mg for 12 weeks in combination with methotrexate, in DMARD-nave participants with early rheumatoid arthritis and active inflammation.

Phase:

PHASE2

Details

Lead Sponsor:

SynAct Pharma Aps

Collaborator:

NBCD A/S

Treatments:

N-(3-(1-(2-nitrophenyl)-1H-pyrrol-2-yl)allylidenamino)guanidine